Interviews

Matthew H. Taylor, MD, Oregon Health and Science University, discusses the toxicities and impact of lenvatinib in the SELECT trial, which treated patients with 131I-refractory differentiated thyroid cancer.

Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado Denver, discusses the future of androgen receptors in breast cancer.

Marcia S. Brose, MD, PhD, discusses the SELECT trial, which looks at lenvatinib for patients with 131I-refractory differentiated thyroid cancer.

Bishoy M. Faltas, MD, Fellow, Hematology/Oncology, Weill Cornell Medical College, discusses immunotherapy in platinum-resistant bladder cancer.

Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the challenges associated with utilizing new agents in HER2-positive breast cancer.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses bacillus calmette-guerin (BCG) therapy for the treatment of patients with non-invasive bladder cancer.

Gordon B. Mills, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses assay of the genome in order to further measure DNA and RNA.

Brock O'Neil, MD, physician instructor in urologic surgery, Vanderbilt University, discusses robotic prostatectomy versus open surgery.

Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of surgery, director, urologic oncology, University of Chicago Medicine, discusses the challenges in treating bladder cancer.

Ingrid A. Mayer, MD, MSCI, discusses patient selection for emerging therapies in patients with ER-positive metastatic breast cancer (mBC).

Xiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies in high-grade prostate cancer.

Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses patient selection for platinum-based therapy in triple-negative breast cancer (TNBC).

Eric Van Cutsem, MD, PhD, discusses regorafenib for the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC).

Roy S. Herbst, MD, PhD, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, discusses immunotherapy in squamous and nonsquamous non-small cell lung cancer (NSCLC).

Nooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses the challenges of treating HPV-induced tumors.

Robert L. Coleman, MD, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the toxicities associated with rucaparib in patients with ovarian cancer.

Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses the ELOQUENT-2 study in patients with relapsed/refractory multiple myeloma.

Jason J. Luke, MD, FACP, assistant professor of medicine, The University of Chicago, discusses the efficacy of PD-1/PD-L1 inhibitors in melanoma.

Philip McCarthy, MD, professor of oncology, director, Blood and Marrow Transplant Center, Department of Medicine, Roswell Park Cancer Institute, discusses the toxicities associated with lenalidomide for multiple myeloma in the CALGB 100104 study.

Andrew Hendifar, MD, MPH, assistant professor of medicine, Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses PEGPH20 with nab-paclitaxel/gemcitabine in pancreatic cancer.

Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the results of the METGastric study.

Sarah Holstein, MD, PhD, assistant professor of oncology, Roswell Park Cancer Institute, discusses a randomized study that compared lenalidomide with placebo for patients with multiple myeloma, following a single autologous stem cell transplant (ASCT).

Philip Philip MD, PhD, professor of oncology at Karmanos Cancer Center, Wayne State University School of Medicine, discusses current research on pancreatic cancer, as well as funding, awareness, and treatment options.

Jeffrey Jones, MD, MPH, assistant professor, Internal Medicine, section head, Chronic Lymphocytic Leukemia (CLL) research program, Ohio State University, discusses idelalisib (Zydelig) for previously treated CLL.

John Zalcberg, PhD, medical oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses a randomized phase II study of regorafenib in refractory advanced oesophago-gastric cancer (AOGC).

Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the treatment of metastatic triple-negative breast cancer (TNBC).

Rowan T. Chlebowski, MD, PhD, professor and chief, Harbor-University of California Los Angeles Medical Center, Department of Internal Medicine, Medical Oncology/Hematology, discusses breast cancer prevention.

Matthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco, discusses the impact of immunotherapy on the treatment of prostate cancer. Cooperberg believes immunotherapy treatment should be used earlier in the course of the disease.

Paul A. Bunn, Jr., MD, distinguished professor, Division of Medical Oncology, University of Colorado, James Dudley Chair in Lung Cancer Research, Lung Cancer: Giant of Cancer Care, discusses immunotherapy in lung cancer.

Ravi Vij, MD, associate professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, discusses the monoclonal antibody daratumumab for the treatment of patients with heavily pretreated multiple myeloma.